About Clearside Biomedical (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631
Debt
Debt-to-Equity Ratio0.22%
Current Ratio2.90%
Quick Ratio2.90%
Price-To-Earnings
Trailing P/E Ratio-4.90
Forward P/E Ratio-5.03
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales1,071.80
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book13.60
Profitability
EPS (Most Recent Fiscal Year)($2.33)
Net Income$-58,970,000.00
Net Margins-17,094.20%
Return on Equity-131.22%
Return on Assets-96.00%
Miscellaneous
Employees34
Outstanding Shares31,910,000
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical (NASDAQ:CLSD) posted its quarterly earnings data on Wednesday, March, 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.05. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.10 million. Clearside Biomedical had a negative net margin of 17,094.20% and a negative return on equity of 131.22%. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
5 brokers have issued 12-month price targets for Clearside Biomedical's stock. Their predictions range from $15.00 to $29.00. On average, they expect Clearside Biomedical's stock price to reach $21.80 in the next twelve months. View Analyst Ratings for Clearside Biomedical.
Are investors shorting Clearside Biomedical?
Clearside Biomedical saw a increase in short interest in March. As of March 15th, there was short interest totalling 1,507,557 shares, an increase of 56.1% from the February 28th total of 965,841 shares. Based on an average daily volume of 3,756,703 shares, the short-interest ratio is presently 0.4 days. Approximately 8.3% of the shares of the company are short sold.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include AMAG Pharmaceuticals (AMAG), Omeros (OMER), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), NuCana (NCNA), Endocyte (ECYT), Adamas Pharmaceuticals (ADMS), Rocket Pharmaceuticals (RCKT), Rhythm Pharmaceuticals (RYTM), Lannett (LCI), Geron (GERN), Ziopharm Oncology (ZIOP), Odonate Therapeutics (ODT), Five Prime Therapeutics (FPRX), BeyondSpring (BYSI), Rigel Pharmaceuticals (RIGL), Aduro BioTech (ADRO) and Kura Oncology (KURA).
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Christy L. Shaffer Ph.D., Chairman of the Board (Age 59)
- Daniel H. White, President, Chief Executive Officer, Director (Age 50)
- Charles A. Deignan, Chief Financial Officer (Age 52)
- Glenn Noronha Ph.D., Chief Scientific Officer (Age 52)
- Rafael V. Andino, Vice President - Engineering & Manufacturing
- George Lasezkay J.D., Director (Age 65)
- Gerald D. Cagle Ph.D., Independent Director (Age 72)
- Richard J. Croarkin, Independent Director (Age 62)
- William D. Humphries, Independent Director (Age 50)
- Clay B. Thorp, Independent Director (Age 48)
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Has Clearside Biomedical been receiving favorable news coverage?
News coverage about CLSD stock has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clearside Biomedical earned a coverage optimism score of 0.21 on Accern's scale. They also gave media coverage about the company an impact score of 45.52 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $11.42.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $368.28 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clearside Biomedical (NASDAQ:CLSD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Clearside Biomedical in the last 12 months. Their average twelve-month price target is $21.80, suggesting that the stock has a possible upside of 90.89%. The high price target for CLSD is $29.00 and the low price target for CLSD is $15.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.80 | $21.80 | $20.00 | $20.50 |
| Price Target Upside: | 90.89% upside | 82.43% upside | 166.31% upside | 156.25% upside |
Clearside Biomedical (NASDAQ:CLSD) Consensus Price Target History
Clearside Biomedical (NASDAQ:CLSD) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Clearside Biomedical (NASDAQ:CLSD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Clearside Biomedical (NASDAQ CLSD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 20.90%
Institutional Ownership Percentage: 38.63%
Clearside Biomedical (NASDAQ CLSD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/23/2018 | Charles A Deignan | CFO | Buy | 500 | $11.79 | $5,895.00 | 66,356 |  |
| 3/22/2018 | Gerald D Cagle | Director | Buy | 7,500 | $11.89 | $89,175.00 | 23,441 | |
| 12/7/2017 | Clay Thorp | Director | Sell | 5,000 | $6.13 | $30,650.00 | | |
| 12/5/2017 | Clay Thorp | Director | Sell | 15,000 | $6.37 | $95,550.00 | | |
| 11/16/2017 | Clay Thorp | Director | Sell | 35,000 | $7.00 | $245,000.00 | | |
| 11/14/2017 | Clay Thorp | Director | Sell | 15,000 | $7.02 | $105,300.00 | | |
| 10/19/2017 | Daniel H White | Insider | Sell | 8,000 | $7.82 | $62,560.00 | 477,935 | |
| 10/5/2017 | Clay Thorp | Director | Sell | 35,000 | $8.57 | $299,950.00 | | |
| 9/15/2017 | Clay Thorp | Director | Sell | 24,500 | $7.52 | $184,240.00 | | |
| 9/14/2017 | Clay Thorp | Director | Sell | 6,000 | $7.52 | $45,120.00 | | |
| 9/13/2017 | Clay Thorp | Director | Sell | 8,500 | $7.49 | $63,665.00 | | |
| 9/8/2017 | Daniel H White | Insider | Sell | 16,000 | $7.57 | $121,120.00 | 486,935 | |
| 8/15/2017 | Christy L Shaffer | Director | Buy | 1,100 | $7.00 | $7,700.00 | 4,400 | |
| 8/14/2017 | Charles A Deignan | CFO | Buy | 1,000 | $7.07 | $7,070.00 | 65,309 | |
| 8/11/2017 | Gerald D Cagle | Director | Buy | 5,000 | $7.08 | $35,400.00 | 15,941 | |
| 8/9/2017 | Clay Thorp | Director | Sell | 24,500 | $7.57 | $185,465.00 | | |
| 8/8/2017 | Clay Thorp | Director | Sell | 5,000 | $7.98 | $39,900.00 | | |
| 8/7/2017 | Clay Thorp | Director | Sell | 4,500 | $8.02 | $36,090.00 | | |
| 7/20/2017 | Daniel H White | Insider | Sell | 8,000 | $9.75 | $78,000.00 | 499,967 | |
| 7/19/2017 | Daniel H White | CEO | Sell | 3,600 | $9.79 | $35,244.00 | 499,967 | |
| 6/14/2017 | Daniel H White | Insider | Sell | 8,000 | $7.89 | $63,120.00 | 504,067 | |
| 6/13/2017 | Daniel H White | CEO | Sell | 3,600 | $7.78 | $28,008.00 | 504,067 | |
| 5/22/2017 | Christy L Shaffer | Director | Buy | 1,100 | $8.00 | $8,800.00 | 3,300 | |
| 5/19/2017 | Clay Thorp | Director | Sell | 24,000 | $8.36 | $200,640.00 | | |
| 5/18/2017 | Daniel H White | Insider | Sell | 8,000 | $8.41 | $67,280.00 | 511,267 | |
| 5/17/2017 | Clay Thorp | Director | Sell | 44,485 | $8.63 | $383,905.55 | | |
| 5/16/2017 | Clay Thorp | Director | Sell | 9,544 | $8.61 | $82,173.84 | | |
| 5/15/2017 | Clay Thorp | Director | Sell | 15,941 | $8.94 | $142,512.54 | | |
| 4/19/2017 | Clay Thorp | Director | Sell | 68,485 | $7.46 | $510,898.10 | | |
| 4/18/2017 | Clay Thorp | Director | Sell | 44,455 | $7.48 | $332,523.40 | | |
| 4/17/2017 | Clay Thorp | Director | Sell | 22,000 | $7.43 | $163,460.00 | | |
| 4/4/2017 | Daniel H White | Insider | Sell | 8,000 | $7.55 | $60,400.00 | 527,217 | |
| 4/3/2017 | Daniel H White | CEO | Sell | 3,600 | $7.56 | $27,216.00 | 527,217 | |
| 3/20/2017 | Christy L Shaffer | Director | Buy | 2,200 | $6.90 | $15,180.00 | 2,200 | |
| 3/16/2017 | Clay Thorp | Director | Sell | 68,485 | $6.56 | $449,261.60 | | |
| 2/22/2017 | Clay Thorp | Director | Sell | 27,000 | $7.55 | $203,850.00 | | |
| 2/17/2017 | Clay Thorp | Director | Sell | 41,485 | $7.60 | $315,286.00 | | |
| 1/20/2017 | Clay Thorp | Director | Sell | 68,485 | $8.53 | $584,177.05 | | |
| 1/19/2017 | Venture Advisors Iii Hatteras | Insider | Sell | 25,301 | $8.63 | $218,347.63 | | |
| 6/7/2016 | Clay Thorp | Director | Sell | 138 | $7.00 | $966.00 | | |
| 6/7/2016 | Venture Advisors Iv S Hatteras | Major Shareholder | Buy | 414,286 | $7.00 | $2,900,002.00 | | |
(Data available from 1/1/2013 forward)
Clearside Biomedical (NASDAQ CLSD) News Headlines
| Source: |
|
Clearside Biomedical (NASDAQ:CLSD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Clearside Biomedical (NASDAQ:CLSD) Income Statement, Balance Sheet and Cash Flow Statement
Clearside Biomedical (NASDAQ CLSD) Stock Chart for Friday, April, 20, 2018
Loading chart…
